Article published on Alzinova’s participation at the CTAD conference
Date: 2026-10-15
Longevity.Technology has published an article about Alzinova and the company’s participation at the CTAD conference. The article highlights Alzinova’s Alzheimer’s vaccine candidate, ALZ-101, and the Phase II ADVANCE trial, which will be presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston.